You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
拓新藥業(301089.SZ):不掌握阿茲夫定新冠藥適應症臨牀試驗情況
格隆匯 01-20 22:21

格隆匯1月20日丨拓新藥業(301089.SZ)發佈股票交易異常波動公吿,公司不在默沙東的合格供應商名錄系統中,公司未與默沙東簽署任何合作協議,與其不存在合作關係,未向默沙東供應尿苷產品。尿苷作為醫藥中間體生產工藝較為成熟,不存在較高的技術壁壘及市場準入門檻。2020年和2021年1-9月,尿苷產品佔公司各期營業收入的比例分別為11.02%和9.63%,對業績影響不大。目前,公司無在手尿苷訂單。

阿茲夫定是一種艾滋病毒逆轉錄酶抑制劑,公司子公司新鄉製藥股份有限公司阿茲夫定原料藥通過了與阿茲夫定製劑的關聯審評。公司子公司新鄉製藥股份有限公司僅僅是阿茲夫定原料藥的生產企業,不掌握阿茲夫定新冠藥適應症臨牀試驗情況,阿茲夫定新冠適應症是否獲批、獲批時間及對公司的影響具有不確定性,請投資者注意市場風險。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account